[Development of monoclonal antibody therapy for brain tumors].
Mishima
Kazuhiko
K
Department of Neurosurgery, Saitama Medical School.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy*; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000235:genetics / Q000276:immunology; D015321:Gene Rearrangement / Q000235:genetics; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy; D051379:Mice; D009389:Neovascularization, Pathologic / Q000276:immunology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D000069283:Rituximab; D019063:Tenascin / Q000276:immunology; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; D000069283:Rituximab; D019063:Tenascin; D042461:Vascular Endothelial Growth Factor A